Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study.

Autor: Cavanna F; Departamento de Física, Universidad de Buenos Aires and Instituto de Física de Buenos Aires (IFIBA - CONICET), Pabellón I, Ciudad Universitaria (1428), CABA, Buenos Aires, Argentina.; Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia (FLENI), Montañeses 2325, C1428 CABA, Buenos Aires, Argentina., Muller S; Departamento de Física, Universidad de Buenos Aires and Instituto de Física de Buenos Aires (IFIBA - CONICET), Pabellón I, Ciudad Universitaria (1428), CABA, Buenos Aires, Argentina., de la Fuente LA; Departamento de Física, Universidad de Buenos Aires and Instituto de Física de Buenos Aires (IFIBA - CONICET), Pabellón I, Ciudad Universitaria (1428), CABA, Buenos Aires, Argentina.; Institute of Cognitive and Translational Neuroscience, INECO Foundation, Favaloro University, Buenos Aires, Argentina., Zamberlan F; Departamento de Física, Universidad de Buenos Aires and Instituto de Física de Buenos Aires (IFIBA - CONICET), Pabellón I, Ciudad Universitaria (1428), CABA, Buenos Aires, Argentina.; Department of Cognitive Science and Artificial Intelligence, Tilburg University, Tilburg, the Netherlands., Palmucci M; Departamento de Física, Universidad de Buenos Aires and Instituto de Física de Buenos Aires (IFIBA - CONICET), Pabellón I, Ciudad Universitaria (1428), CABA, Buenos Aires, Argentina., Janeckova L; Forensic Laboratory of Biologically Active Substances, Department of Chemistry of Natural Compounds, University of Chemistry and Technology Prague, Prague, Czech Republic., Kuchar M; Forensic Laboratory of Biologically Active Substances, Department of Chemistry of Natural Compounds, University of Chemistry and Technology Prague, Prague, Czech Republic.; Department of Experimental Neurobiology, National Institute of Mental Health, Klecany, Czech Republic., Pallavicini C; Departamento de Física, Universidad de Buenos Aires and Instituto de Física de Buenos Aires (IFIBA - CONICET), Pabellón I, Ciudad Universitaria (1428), CABA, Buenos Aires, Argentina.; Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia (FLENI), Montañeses 2325, C1428 CABA, Buenos Aires, Argentina., Tagliazucchi E; Departamento de Física, Universidad de Buenos Aires and Instituto de Física de Buenos Aires (IFIBA - CONICET), Pabellón I, Ciudad Universitaria (1428), CABA, Buenos Aires, Argentina. tagliazucchi.enzo@googlemail.com.; Latin American Brain Health Institute (BrainLat), Universidad Adolfo Ibañez, Santiago de Chile, Chile. tagliazucchi.enzo@googlemail.com.
Jazyk: angličtina
Zdroj: Translational psychiatry [Transl Psychiatry] 2022 Aug 02; Vol. 12 (1), pp. 307. Date of Electronic Publication: 2022 Aug 02.
DOI: 10.1038/s41398-022-02039-0
Abstrakt: The use of low sub-perceptual doses of psychedelics ("microdosing") has gained popularity in recent years. Although anecdotal reports claim multiple benefits associated with this practice, the lack of placebo-controlled studies severely limits our knowledge of microdosing and its effects. Moreover, research conducted in standard laboratory settings could fail to capture the motivation of individuals engaged or planning to engage in microdosing protocols, thus underestimating the likelihood of positive effects on creativity and cognitive function. We recruited 34 individuals starting to microdose with psilocybin mushrooms (Psilocybe cubensis), one of the materials most frequently used for this purpose. Following a double-blind placebo-controlled experimental design, we investigated the acute and short-term effects of 0.5 g of dried mushrooms on subjective experience, behavior, creativity (divergent and convergent thinking), perception, cognition, and brain activity. The reported acute effects were significantly more intense for the active dose compared to the placebo, but only for participants who correctly identified their experimental condition. These changes were accompanied by reduced EEG power in the theta band, together with preserved levels of Lempel-Ziv broadband signal complexity. For all other measurements there was no effect of microdosing except for few small changes towards cognitive impairment. According to our findings, low doses of psilocybin mushrooms can result in noticeable subjective effects and altered EEG rhythms, but without evidence to support enhanced well-being, creativity and cognitive function. We conclude that expectation underlies at least some of the anecdotal benefits attributed to microdosing with psilocybin mushrooms.
(© 2022. The Author(s).)
Databáze: MEDLINE
Externí odkaz: